From Ex Vivo to In Vivo: A Paradigm Shift in Gene Therapy Historically, genome‑editing therapeutics (e.g., Casgevy) have relied on an Ex Vivo approach in which patient cells are harvested, edited outside the body, and then reinfused. While this method minimizes immune rejection, it requires hematopoietic stem‑cell collection, complex ex vivo culture, and intensive myeloablative conditioning, imposing substantial physical and economic burdens on patients. Intellia Therapeutics' recent FDA filing announces that a fully In Vivo genome‑editing strategy—delivering the therapeutic directly into the patient’s vasculature without cell extraction—has entered the final regulatory approval stage, marking a historic transition.

LNP‑CRISPR Architecture: Hepatocyte Targeting and ApoE‑Mediated Uptake Mechanism Intellia's core technology is a lipid nanoparticle (LNP) delivery system. LNPs encapsulating Cas9 mRNA and a single‑guide RNA (sgRNA) acquire a selective coating of the serum protein apolipoprotein E (ApoE) while circulating. This property directs the particles to the highly expressed LDL receptors on hepatocyte surfaces, facilitating precise endocytic uptake. After endosomal escape, the mRNA is translated into Cas9 protein; the Cas9‑sgRNA complex translocates to the nucleus and permanently knocks out disease‑causing TTR alleles responsible for hereditary transthyretin amyloidosis (ATTR).

Transient Expression and Permanent Correction: Superior Safety Profile Compared with Viral Vectors The decisive advantage of this platform over viral vectors such as AAV lies in its transient expression. AAV genomes persist in host cells, leading to prolonged transgene expression and a persistent risk of off‑target editing and insertional mutagenesis‑driven oncogenesis. In contrast, LNP‑delivered mRNA mediates a brief window of target‑gene cleavage before being fully degraded by endogenous nucleases. Thus, a single dose can permanently eliminate the genetic lesion while the editing machinery disappears without trace, achieving an optimal balance of efficacy and genotoxic safety.

Democratizing One‑Shot Curative Therapies and Liberating Genomic Medicine Infrastructure This IND submission is transformative because it opens a commercial pathway to dramatically lower the cost of gene‑therapy production and administration. Unlike Ex Vivo products that require patient‑specific manufacturing, the In Vivo LNP‑CRISPR platform can be produced at scale as an off‑the‑shelf commodity, stored in hospital pharmacies, and administered via intravenous infusion on demand. This not only expands access to rare‑disease treatments but also establishes a regulatory precedent for programmable, organ‑specific LNP capsids—where only the guide sequence is altered—to be deployed across liver, lung, spleen, and other targets.